Abstract
Abstract
Background
Paromomycin is a 2-deoxystreptamine aminocyclitol aminoglycoside antibiotic with broad spectrum activity against Gram-negative, Gram-positive bacteria and many protozoa. This study introduces a strategy for paromomycin production through solid-state fermentation using Streptomyces rimosus subsp. paromomycinus NRRL 2455. Solid state fermentation has gained enormous attention in the development of several products because of their numerous advantages over submerged liquid fermentation. After selecting the best solid substrate, a time course study of paromomycin production was carried out followed by optimization of environmental conditions using response surface methodology. Paromomycin yields obtained using this technique were also compared to those obtained using submerged liquid fermentation.
Results
Upon screening of 6 different substrates, maximum paromomycin concentration (0.51 mg/g initial dry solids) was obtained with the cost-effective agro-industrial byproduct, corn bran, impregnated with aminoglycoside production media. Optimization of environmental conditions using D-optimal design yielded a 4.3-fold enhancement in paromomycin concentration reaching 2.21 mg/g initial dry solids at a pH of 8.5, inoculum size of 5% v/w and a temperature of 30 °C.
Conclusion
Compared to submerged liquid fermentation, solid state fermentation resulted in comparable paromomycin concentrations, cost reduction of raw materials, less energy consumption and waste water discharge, which have major implications in industrial fermentation. Therefore, solid state fermentation is a promising alternative to submerged liquid fermentation for paromomycin production. To the best of our knowledge, this is the first report on the optimized paromomycin production through solid state fermentation process.
Publisher
Springer Science and Business Media LLC
Subject
Microbiology (medical),Microbiology
Reference58 articles.
1. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents. 2009;33:201–5. https://doi.org/10.1016/j.ijantimicag.2008.09.001.
2. Takahashi Y, Igarashi M. Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’. J Antibiot. 2018;71:4–14. https://doi.org/10.1038/ja.2017.117.
3. Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother. 2013;14:1585–97. https://doi.org/10.1517/14656566.2013.806486.
4. Frohardt R, Haskell TH, John E, K. P: Antibiotic and methods for obtaining same: United states patent office. 1959, US2916485A, https://patents.google.com/patent/US2916485
5. Jamil KM, Haque R, Rahman R, Faiz MA, ATMRH B, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, et al. Effectiveness study of Paromomycin IM injection (PMIM) for the treatment of visceral Leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015;9:e0004118. https://doi.org/10.1371/journal.pntd.0004118.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献